Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab

NCT05694884 is registered in ClinicalTrials.gov with ASLAN Pharmaceuticals as lead sponsor.

NCT NCT05694884
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05694884 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled, Multicenter Trial to Evaluate the Efficacy and Safety of Eblasakimab in Male or Female Moderate-to-Severe Atopic Dermatitis Patients Previously Treated With Dupilumab
Lead sponsor
ASLAN Pharmaceuticals
Phase
Phase 2
Overall status
Unknown status
Start date
December 21, 2022
Completion date
February 28, 2025
Enrollment
75 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis